01541 IMMUNEONCO-B
- 14.680
- +0.160+1.10%
IMMUNEONCO-B News
ImmuneOnco Completes Filing With China Regulator for Conversion of H Shares
ImmuneOnco Biopharmaceuticals (HKG:1541) completed the filing with China's securities regulator for the conversion of 120.5 million unlisted shares into H-shares, according to a Wednesday filing with
Yiming Angko-B (01541): The China Securities Regulatory Commission issued a notice of record regarding the full circulation of certain H shares of the company's unlisted shares
According to the Zhitong Finance App, Yiming Angko-B (01541) issued an announcement. The company has recently received a filing notice from the China Securities Regulatory Commission to implement the full circulation of the company's H shares. According to the filing notice, the company has completed the implementation filing with the China Securities Regulatory Commission on the conversion of up to 120 million unlisted shares of the company to H shares of the company. The filing notice is valid for 12 months from May 14, 2024. The company will apply to the Stock Exchange for approval to list and trade the relevant H shares on the main board of the Stock Exchange. As of the date of this announcement, the details of the implementation plan for conversion and listing have not been finalized.
Yiming Angko-B (01541.HK) appoints Guan Mei as Executive Director
Gelonghui, May 28 | Yiming Angko-B (01541.HK) announced that after shareholders' approval at the annual shareholders' meeting, Ms. Guan Mei was appointed as the executive director of the first board of directors. Ms. Kwan's term of office will begin on May 28, 2024 and end when the first term of the board expires.
Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China
Immuneonco Biopharmaceuticals (HKG:1541) has obtained approval from the National Medical Products Administration of China to conduct a phase III clinical trial of IMM01 (Timdarpacept) in combination w
Yiming Angko-B (01541.HK): IMM01 (tidapecip) combined with azacitidine was approved by the State Drug Administration to conduct a randomized, double-blind, controlled phase III clinical trial plan
Gelonghui, May 17 | Yiming Angko-B (01541.HK) issued an announcement. The Group was approved by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”) to conduct a randomized, double-blind, controlled IMM01 (tidapecip) combined with azacitidine phase III clinical trial plan for first-line treatment of high-risk myelodysplastic syndrome (HRMDS). Furthermore, the latest results of the IMM01 (tidapecip) combined with azacitidine phase II clinical trial program have been accepted by the 2024 American Society of Clinical Oncology (“ASC”) to be held in Chicago on June 1, 2024
Chairman of Yiming Angke Tian Wenzhi: Plans to conduct a III mid-term analysis as early as the end of next year, BD cooperation is being promoted | Financial Interview
① Yiming Angke is firmly promoting its CD47 pipeline clinical trial. What is the ambition and prospects of the company All in CD47? ② Tian Wenzhi revealed that Yiming Angke is actively communicating overseas licensing cooperation for pipeline products with overseas pharmaceutical companies, hoping to add more cash flow to the company. At the same time, he said that the company is confident that B can be harvested within five years.
宜明昂科-B：2023年報
Featured announcements | Xiaopeng and Volkswagen reached a strategic technical cooperation; Sands China's total net revenue increased 42% year over year
Anta Sports: The retail value of Anta brand products achieved a positive year-on-year increase in the number of units in the first quarter; China Building Materials expects a 147% year-on-year increase in net loss for the first quarter.
Yiming Angko-B (01541.HK): IMM01 (tidapecip) was approved by the State Drug Administration for phase III clinical trial program
Gelonghui, April 17 | Yiming Angko-B (01541.HK) announced that in April 2024, the Group has obtained approval from the China National Drug Administration for recurrent or refractory (R/R) classic Hodgkin lymphoma (cL) that recurs or progresses after treatment with IMM01 (tidapacept) and tirelizumab in combination therapy with procedural cellular death protein 1 (PD-1) inhibitors. The Group's core product IMM01 (tidapecip) is an innovative targeting differentiation cluster 47 (CD47) molecule. This product is the first to enter China
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases
Immuneonco Biopharmaceuticals' (HKG:1541) loss narrowed to 379.5 million yuan or 1.05 yuan per share, in 2023, from 402.9 million yuan, or 1.21 yuan per share, in 2022, according to a Tuesday filing w
Yiming Enko-B (01541.HK) reduced its annual net loss to 380 million yuan, continuing to rapidly advance the development of drug pipelines
On March 25, GLONGHUI | Yiming Angko-B (01541.HK) announced its annual results. The Group's loss during the year was reduced from RMB 402.9 million for the year ended December 31, 2022 to RMB 379.5 million for the year ended December 31, 2023. R&D expenditure increased 5.3% from RMB 277.3 million for the year ended 31 December 2022 to RMB 291.9 million for the year ended 31 December 2023, mainly due to (i) an increase of RMB 24 in clinical trial expenses due to the progress of clinical drug candidates
Yiming Onko-B (01541) will continue to support R&D in 2023
Yiming Angko-B (01541) announced its 2023 results, with revenue of about 386,000 yuan and an increase in R&D expenses by 5...
IMMUNEONCO-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Changes in Hong Kong stocks | Yiming Enko-B (01541) quickly rose by more than 20%. The company will hold a board meeting next Monday to consider and approve annual results
Yiming Enko-B (01541) quickly rose by more than 20%. As of press release, it rose 20.27% to HK$17.8, with a turnover of HK$3.31 million.
Yiming Enko-B (01541.HK) held a board meeting on March 25 to consider and approve the annual results
Glonghui, March 13 | Yiming Enko-B (01541.HK) announced that the company will hold a board meeting on March 25, 2024 (Monday) to consider and approve the results and publication of the company and its subsidiaries for the year ended 31 December 2023, and to consider recommending payment of a final dividend (if any).
IMMUNEONCO-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks 丨 The new Hong Kong Stock Connect concept continues to strengthen, Yiming, Anke and the fourth paradigm soared by more than 90%
Glonghui, March 7 | In the Hong Kong stock market, some individual stocks newly included in the Hong Kong Stock Connect have strengthened recently. Among them, Yiming Angke soared 97% in the intraday period, 92% in the fourth paradigm, 61%, Ruipu Lanjun rose 47%, Junshengtai Pharmaceutical rose 30%, and the pot industry rose 30%.
Changes in Hong Kong stocks | Yiming Enko-B (01541) rebounded more than 8%, and the stock price fell to 40% in the past 7 trading days. The company confirmed that business operations remained normal
Yiming Enko-B (01541) has rebounded by more than 8%. The stock price has continued to fall recently, with a cumulative decline of more than 40% over the past 7 trading days. As of press release, it rose 8.19% to HK$15.58, with a turnover of HK$3.614,800.
Selected announcements | JD's Q4 revenue is 306.1 billion yuan, and plans to repurchase shares of 3 billion US dollars; Ping An of China expects last year's dividend net profit to account for no less than 40%
JD Logistics's revenue in 2023 was 166.6 billion yuan, with external customers accounting for 70% of revenue; Aobo Holdings' net gaming revenue in 2023 exceeded HK$20 billion, an increase of 229.3% over the previous year.
Analysis
Price Target
No Data
